|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
310,240,000 |
Market
Cap: |
6.87(B) |
Last
Volume: |
2,595,680 |
Avg
Vol: |
2,443,625 |
52
Week Range: |
$18.78 - $24.13 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 14.9 |
Insider 6 Months : 16.6 |
Insider 3/6 Months : 32 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
2 |
2 |
2 |
Total Shares Sold |
66,225 |
325,783 |
532,046 |
1,028,448 |
Total Sell Value |
$1,469,691 |
$7,234,582 |
$11,431,100 |
$20,278,991 |
Total People Sold |
2 |
4 |
5 |
11 |
Total Sell Transactions |
2 |
8 |
12 |
26 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-11-15 |
4 |
D |
$18.10 |
$1,125,150 |
D/D |
(62,163) |
349,077 |
|
- |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-11-15 |
4 |
AS |
$18.09 |
$859,275 |
D/D |
(47,500) |
411,240 |
|
22% |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-11-15 |
4 |
OE |
$6.21 |
$294,975 |
D/D |
47,500 |
458,740 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2021-11-15 |
4 |
D |
$18.10 |
$3,507,418 |
D/D |
(193,780) |
367,288 |
|
- |
|
Hessekiel Jeffrey |
EVP and General Counsel |
|
2021-11-01 |
4 |
AS |
$22.03 |
$112,728 |
D/D |
(5,117) |
632,825 |
|
-6% |
|
Morrissey Michael M |
President and CEO |
|
2021-10-22 |
4 |
D |
$21.33 |
$527,854 |
D/D |
(24,747) |
561,068 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2021-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
94,002 |
585,815 |
|
- |
|
Hessekiel Jeffrey |
EVP and General Counsel |
|
2021-10-15 |
4 |
AS |
$22.02 |
$283,684 |
D/D |
(12,883) |
637,942 |
|
-6% |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-10-15 |
4 |
AS |
$21.92 |
$1,041,200 |
D/D |
(47,500) |
411,240 |
|
-6% |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-10-15 |
4 |
OE |
$6.21 |
$294,975 |
D/D |
47,500 |
458,740 |
|
- |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-09-30 |
4 |
D |
$20.63 |
$148,062 |
D/D |
(7,177) |
411,240 |
|
- |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
28,950 |
418,417 |
|
- |
|
Hessekiel Jeffrey |
EVP and General Counsel |
|
2021-09-30 |
4 |
D |
$20.63 |
$156,644 |
D/D |
(7,593) |
650,825 |
|
- |
|
Hessekiel Jeffrey |
EVP and General Counsel |
|
2021-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
28,950 |
658,418 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2021-09-30 |
4 |
D |
$20.63 |
$176,861 |
D/D |
(8,573) |
415,528 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2021-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
32,567 |
424,101 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-09-30 |
4 |
D |
$20.63 |
$111,732 |
D/D |
(5,416) |
304,528 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
28,950 |
309,944 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2021-09-21 |
4 |
D |
$20.33 |
$1,119,309 |
D/D |
(55,057) |
391,534 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2021-09-21 |
4 |
OE |
$3.66 |
$329,400 |
D/D |
90,000 |
446,591 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-09-16 |
4 |
AS |
$20.36 |
$509,000 |
D/D |
(25,000) |
280,994 |
|
-15% |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-09-16 |
4 |
OE |
$1.70 |
$42,500 |
D/D |
25,000 |
305,994 |
|
- |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-09-15 |
4 |
AS |
$20.46 |
$971,850 |
D/D |
(47,500) |
389,467 |
|
-12% |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-09-15 |
4 |
OE |
$6.21 |
$294,975 |
D/D |
47,500 |
436,967 |
|
- |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-08-16 |
4 |
AS |
$18.44 |
$1,014,200 |
D/D |
(55,000) |
389,467 |
|
3% |
|
1414 Records found
|
|
Page 9 of 57 |
|
|